Studies blood samples and memory tests in people with early Alzheimer's disease
Collects blood samples and memory tests from adults with early Alzheimer's disease.
Plain-language title generated from the registry record
Registry title: Precision Medicine in Alzheimer's Disease : Integration of Resilience Metrics and Risk Factors - Validation Cohort BioCogBank-AD
Key facts
- Where
- Paris, FranceSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 50 to 90 with Alzheimer's disease confirmed by spinal fluid tests, in the mild stage.
- Age
- 50 to 90 years old
- Sex
- All sexes can join
- Disease stage
- Alzheimer's disease by IWG-2 2014 criteria, with MMSE of 20 or more (mild stage)
- Earlier treatment
- People in an Alzheimer's treatment trial cannot join
- Biomarker or test result
- Abnormal CSF Aβ42 or Aβ40/Aβ42 ratio, and abnormal CSF phosphorylated and total Tau, by local cut-offs
Main reasons for not taking part
- Another cause of dementia
- Taking part in an Alzheimer's treatment trial
- Protected adults, including people under guardianship by court order
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 90 years old?
Source: NCT06582199, who can take part
Where in France
- Hôpital CochinParis, FranceContact: Olivier HANON, MD, PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Trial code
- NCT06582199
- Record updated
- 27 March 2026
- Original description
BioCogBankAD aims at building a prospective clinical practice cohort of 244 patients with biologically confirmed mild cognitive impairment due to Alzheimer's Disease (AD) or mild AD in order to validate data regarding markers of resilience toward AD pathophysiological process discovered in an upstream project called AD-Resilience.Read full original descriptionShow less
Precision Medicine in Alzheimer's Disease: Integration of Resilience Metrics and Risk Factors - Validation Cohort BioCogBank-AD
BioCogBankAD aims at building a prospective clinical practice cohort of 244 patients with biologically confirmed mild cognitive impairment due to Alzheimer's Disease (AD) or mild AD in order to validate data regarding markers of resilience toward AD pathophysiological process discovered in an upstream project called AD-Resilience.
Inclusion: Diagnosis of AD according to IWG-2 2014 criteria; Age 50-90 year old; Affiliated or beneficiary of a social security scheme; MMSE ≥ 20; Abnormal CSF Aβ42 or Aβ40/Aβ42 ratio according to local cut-offs; Abnormal CSF phosphorylated and total Tau according to local cut-offs; Ability to pass neuropsychological assessments; Availability of a brain MRI with T1 volumetric sequence performed within 1 year.
Exclusion: Other cause of dementia; Participation in an AD therapeutic clinical trial; Protected adults (including individual under guardianship by court order),.